Journal
HUMAN VACCINES
Volume 6, Issue 12, Pages 1038-1046Publisher
LANDES BIOSCIENCE
DOI: 10.4161/hv.6.12.13057
Keywords
Japanese encephalitis vaccine; safety; immunogenicity; antibody persistence; chimeric virus vaccine; clinical study
Categories
Funding
- Acambis (Cambridge, UK) now Sanofi Pasteur
Ask authors/readers for more resources
In a randomized, double-blind study, 202 healthy adults were randomized to receive a live, attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and placebo 28 days apart in a cross-over design. A subgroup of 98 volunteers received a JE-CV booster at month 6. Safety, immunogenicity and persistence of antibodies to month 60 were evaluated. There were no unexpected adverse events (AEs) and the incidence of AEs between JE-CV and placebo were similar. There were three serious adverse events (SAE) and no deaths. A moderately severe case of acute viral illness commencing 39 days after placebo administration was the only SAE considered possibly related to immunization. 99% of vaccine recipients achieved a seroprotective antibody titer >= 10 to JE-CV 28 days following the single dose of JE-CV and 97% were seroprotected at month 6. Kaplan Meier analysis showed that after a single dose of JE-CV, 87% of the participants who were seroprotected at month 6 were still protected at month 60. This rate was 96% among those who received a booster immunization at month six. Ninety-five percent of subjects developed a neutralizing titer >= 10 against at least three of the four strains of a panel of wild-type Japanese encephalitis virus (JEV) strains on day 28 after immunization. At month 60, that proportion was 65% for participants who received a single dose of JE-CV and 75% for the booster group. These results suggest that JE-CV is safe, well tolerated and that a single dose provides long-lasting immunity to wild-type strains.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available